The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA-4 or anti-PD1 in murine tumor models.
Seema S. Kantak
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Research Funding - Nektar Therapeutics
Steve Lee
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Murali Addepalli
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Ute Hoch
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Rhoneil Pena
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Yolanda Kirksey
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Deborah H. Charych
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Stephen K. Doberstein
Employment or Leadership Position - Nektar
Stock Ownership - Nektar